To develop drugs that uniquely meet the needs and improve the lives of patients with cardiorenal disease, infectious disease and inflammatory disease.

Pipeline
KBP-5074 for CV disease/Hypertension in CKD patients – Finish Phase 2a / Ready for global Phase 2b

KBP-7072 for multiple drug resistant infections– Finish Phase 1 / Ready for global Phase 2

KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD -- Ready for Phase 1

Read More

MANAGEMENT TEAM
• Zhenhua Huang, PhD/MBA, Founder/Chairman
• Fred Yang, PhD,CDO
• Robert Segal, MD,Deputy CMO
• Vince Benn, PhD/MBA,VP
• Pual Chow, PhD,VP
• Wayne W. Lai, PhD,VP, President/KBP China

ADVISORY BOARD
• Bertram Pitt, MD (US)
• George Bakris, MD (US)
• John McMurray, MD (UK)
• Faiez Zannad, MD (FR)
• Ricard Wunderink, MD (US)

Read More

KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.

Careers Information updated on 27 July, 2017

Positive FDA Type B Meeting on KBP-5074

KBP-7072 obtained QIDP and Fast Track Designations

Presenting the annual meeting of the American Society of Nephrology (ASN)

Read More

Contact Us

Fred Yang, Ph.D, Chief Development Officer          fred.yang@kbpbiosciences.com

116 Village Blvd., Suite 210 Princeton, NJ 08540      Phone: (609) 531-0889(Office) / (267)980-9451(Cell)